'Hepatitis C - Small-Molecule Antivirals Pave the Way for Triple Therapy' Report Available Now.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c82079) has announced the addition of "Stakeholder Opinions: Hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. - Small-Molecule Antivirals Pave the Way for Triple Therapy" to their offering. Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects Side effects Effects of a proposed project on other parts of the firm. and limited efficacy in other patients offer much room for improvement. Several development setbacks over the past 18 months highlight the obstacles in R&D. Scope - In-depth analysis of hepatitis C patient potential and dynamics across the major Western markets - Thorough assessment of unmet needs and shortfalls of current HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. therapy - Review of current clinical trial practice and key drug classes in development for hepatitis C - In-depth discussion of novel hepatitis C pipeline candidates and assessment of their potential in HCV therapy Highlights of this title Due to the suboptimal Suboptimal A solution is called suboptimal if a part of the solution has been optimized without regards to the overall objective. efficacy and safety profile of current standard HCV therapy, there is a large unmet need for drugs with an improved clinical profile. Experts agree that add-on therapy currently seems more promising than interferon or ribavirin ribavirin /ri·ba·vi·rin/ (ri?bah-vi´rin) a broad-spectrum antiviral used in the treatment of severe viral pneumonia caused by respiratory syncytial virus, particularly in high-risk infants; also used in conjunction with interferon replacement approaches. Recent clinical data on small-molecule polymerase and protease inhibitors has sparked high hopes for improving SVR Noun 1. SVR - Russia's intelligence service responsible for foreign operations, intelligence-gathering and analysis, and the exchange of intelligence information; collaborates with other countries to oppose proliferation of weapons of mass destruction, terrorism and rates through triple therapy. Vertexs telaprevir, Schering Ploughs boceprevir and Roches R-1626 currently show the most promising profiles. Further strategies in HCV drug development include host enzyme inhibitors and non-interferon immunomodulators. However, although theoretically highly promising, most candidates are in very early stages of development and not expected to reach the market soon. Key reasons to purchase this title - Review the epidemiological and clinical factors driving new product decisions in hepatitis C as well as unmet needs with current treatment options. - Gain insight through a detailed discussion of key pipeline candidates in late-stage development for hepatitis C. - Understand where concerns and future opportunities lie by learning about the views of key hepatitis B opinion leaders. Content Outline: ABOUT US HEALTHCARE About the Infectious Diseases pharmaceutical analysis team Chapter 1 Executive Summary Chapter 2 Disease Background And Current Treatment Chapter 3 Patient Potential Chapter 4 R&D Approach Chapter 5 Interferons Chapter 6 Small Molecule Antivirals Chapter 7 Immunomodulators (Non-Interferon) Chapter 8 Host Enzyme Inhibitors Appendix A Appendix B List of Tables List of Figures Companies Mentioned: - Biotest AG - Boehringer Ingelheim GmbH - CDC See Control Data, century date change and Back Orifice. CDC - Control Data Corporation SPA - Centerline cen·ter·line n. 1. A line that bisects something into equal parts. 2. A painted line running along the center of a road or highway that divides it into two sections for traffic moving in opposite directions, or, in the case of Holding Company - Flamel Technologies - Friedman Industries - Group 1 Automotive Group 1 Automotive, Inc. NYSE: GPI is a Fortune 1000 company, based in Houston, Texas and founded in 1997. It is one of the five largest automotive retailers in the United States with 143 dealerships in 14 states. , Inc. - HCC Insurance Holdings HCC Insurance Holdings, Inc. , Inc. - Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. Inc. - Idenix Pharmaceuticals, Inc. - Insight Communications Company, Inc. - Kirin Brewery Holdings Company, Limited - Maersk Logistics - Mochida Pharmaceutical Co., Ltd. - Nabi Biopharmaceuticals - Novartis AG - Omega Protein Corporation - Safety Insurance Group, Inc. - Saul Centers, Inc. - Schering-Plough Corporation - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/reports/c82079 Source: Datamonitor |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion